Pharmaceutical News and Articles

Chemo Causes Lasting Physical Decline In Breast Cancer Survivors

Breast cancer survivors treated with chemotherapy tend to suffer a longer-lasting decline in their physical health, compared to women who receive hormone therap

Continuous Glucose Monitors Can Overestimate Blood Sugar Levels, Study Finds

allowing real-time updates on blood sugar levels without the need for repeated finger pricks. But a new small-scale study suggests these devices might not be as

Race-Neutral Formulas Improve Asthma Detection in Black Children

Race plays a role in whether a child is quickly and accurately diagnosed with asthma, a new study suggests. Outdated and flawed studies previously led to the be

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

RFK Jr. Says New HHS Decisions No Longer Required to Be Open for Public Comment

In a policy statement published today in the Federal Register, Robert F. Kennedy Jr., secretary of the U.S. Department of Health and Human Services, has rescind

FDA Approves TNKase (tenecteplase) for the Treatment of Acute Ischemic Stroke in Adults

CDC IDs Trends in Pediatric Flu Deaths With Influenza-Linked Encephalopathy

During the 2010-2011 to 2024-2025 influenza seasons, 9 percent of pediatric influenza-associated deaths had influenza-associated encephalopathy or encephalitis

Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies

Genentech, a member of the Roche Group (SIX RO, ROG OTCQX RHHBY), announced today new positive data from Stage 2 and Stage 3 of the National Institutes of Healt

Omalizumab Treats Multi-Food Allergy Better Than Oral Immunotherapy

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in peop

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

NEWARK, California, OSAKA, Japan and CAMBRIDGE, Massachusetts, March 3, 2025 Protagonist Therapeutics, Inc. ( Protagonist ) (NASDAQ PTGX) and Takeda (TSE 4502 N